These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. A recombinant probiotic for treatment and prevention of cholera. Focareta A; Paton JC; Morona R; Cook J; Paton AW Gastroenterology; 2006 May; 130(6):1688-95. PubMed ID: 16697733 [TBL] [Abstract][Full Text] [Related]
44. Formulation in tablets of a cholera whole cells inactivated vaccine candidate. Talavera A; Año G; Pino Y; Castaño J; Uribarri E; Riverón L; Gil S; Fernández S; Cedré B; Valmaseda T; Pérez JL; Infante JF; García L; Sierra G Vaccine; 2006 Apr; 24(16):3381-7. PubMed ID: 16460846 [TBL] [Abstract][Full Text] [Related]
45. Cholera and the immune response. Holmgren J; Svennerholm AM Prog Allergy; 1983; 33():106-19. PubMed ID: 6338509 [No Abstract] [Full Text] [Related]
46. Antibody cross-reactions with lipopolysaccharide from E. coli O157 after cholera vaccination. Chart H; Rowe B Lancet; 1993 May; 341(8855):1282. PubMed ID: 8098423 [No Abstract] [Full Text] [Related]
47. Simultaneous vaccination against cholera and yellow fever. Felsenfeld O; Wolf RH; Gyr K; Grant LS; Dutta NK Lancet; 1973 Mar; 1(7801):457-8. PubMed ID: 4120368 [No Abstract] [Full Text] [Related]
48. Development and validation of a detection system for wild-type Vibrio cholerae in genetically modified cholera vaccine. Studer E; Candrian U Biologicals; 2000 Sep; 28(3):149-54. PubMed ID: 10964441 [TBL] [Abstract][Full Text] [Related]
50. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. Viret JF; Dietrich G; Favre D Vaccine; 2004 Jun; 22(19):2457-69. PubMed ID: 15193410 [TBL] [Abstract][Full Text] [Related]
51. Vaccines for the future: problems and potential solutions from the countries that need them. Jones T; Badaró R Braz J Infect Dis; 2000 Jun; 4(3):156-60. PubMed ID: 10934500 [No Abstract] [Full Text] [Related]
52. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli. Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752 [TBL] [Abstract][Full Text] [Related]
53. [Cholera update and vaccination problems]. Fournier JM; Villeneuve S Med Trop (Mars); 1998; 58(2 Suppl):32-5. PubMed ID: 9812307 [TBL] [Abstract][Full Text] [Related]
54. Genetic manipulation of Vibrio cholerae for vaccine development: construction of live attenuated El Tor candidate vaccine strains. Benítez JA; Silva AJ; Rodríguez BL; Fando R; Campos J; Robert A; García H; García L; Pérez JL; Oliva R; Torres CA; Ledón T Arch Med Res; 1996; 27(3):275-83. PubMed ID: 8854382 [TBL] [Abstract][Full Text] [Related]
55. Disaster, water, cholera, vaccines, and hope. Drazen JM; Klempner MS N Engl J Med; 2005 Feb; 352(8):827. PubMed ID: 15728816 [No Abstract] [Full Text] [Related]
56. [Evaluation of the ELISA method for cholera toxin determination in Vibrio cholerae cultures]. González-Bonilla C; Gutiérrez-Cogco L; Moguel-Pech L; Villanueva-Zamudio A Rev Latinoam Microbiol; 1994; 36(4):273-6. PubMed ID: 7701137 [TBL] [Abstract][Full Text] [Related]
57. [Air line as a possible vector of quarantine cholera]. Fattorini M Minerva Med; 1973 Sep; 64(68):3550-6. PubMed ID: 4798211 [No Abstract] [Full Text] [Related]
58. [Cholera---the tip of an iceberg]. Ostberg S Lakartidningen; 1979 Mar; 76(13):1185-8. PubMed ID: 431208 [No Abstract] [Full Text] [Related]